







Adult Community IV Antibiotic Treatment: Authorisation to Administer and Administration Record – Ceftriaxone 4g OD

Patient details Name Address NHS number DOB						Allergies & Intolerances: No known allergies Document nature, details and date of				Indication for treatment: Date antibiotic to start in community: Planned treatment length in community or end date:													
					each reaction																		
eGFR:	Cre	atinine:		Date:				Weight (kg): Date:															
Medication			Dose	Frequency		Route		Instructions for preparation and use										Pharm ched	-				
Ceftriaxone			4g	OI	D	IV	requ	Withdraw 40mL sodium chloride 0.9% from a 250mL bag and use to reconstitute the 2g vial (each 2g vial requires 20mL). Shake well until the solution is clear, this may take up to 90 seconds. Return the reconstituted															
Sodium Chloride 0.9%			250mL	OI	D	IV	doses to the infusion bag and mix thoroughly prior to administration Administration: Infuse over 1 hour, preferably into a large vein.																
				NB. An infusion set flush is NOT required as volume ≥250mL ³ .																			
Sodium Chloride 0.9%			Flush the cannula with 5ml of sodium chloride 0.9% or the PICC line withroute.									h-10mL	sodium (chloride ().9% bef	ore and	after ea	ch admi	nistratio	n via IV			
1. Ceftriaxone 2g Powder for solution for injection/infusion. Last updated 19 Jan 2022. Available from Ceftriaxone 2g Powder for solution for injection/infusion - Summary of Product Characteristics (SmPC) - (emc) (medicines.org.uk). 2. Medusa. Ceftriaxone. Intravenous injection. Injectable Medicines Guide. Last updated: Nov 2020. Available from: https://medusa.wales.nhs.uk/ . 3. SOP for Intravenous Infusion Set Flushing — available through NBT LINK/UHBW														table									
Date & time:																							
Given by:																							
Prescriber m	nust be F2 c	or abov	e, or a sui	table no		-	riber.										1						
Signed:					Nar (Print I						Profess registra numbe	ation			Blee _l Tele _l	o/ ohone:			Date:				

Author: Carys Jones (OPAT Pharmacist)
Check by Nathalie Roberts (OPAT Pharmacist)
Authorised by Medicine Governance Group

Review date: June 2025

Version 2

Approval date: June 2023